Myositis News and Research

RSS
Myositis is inflammation of your skeletal muscles, which are also called the voluntary muscles. These are the muscles you consciously control that help you move your body. An injury, infection or autoimmune disease can cause myositis. The diseases dermatomyositis and polymyositis both involve myositis. Polymyositis causes muscle weakness, usually in the muscles closest to the trunk of your body. Dermatomyositis causes muscle weakness, plus a skin rash. Both diseases are usually treated with prednisone, a steroid medicine, and sometimes other medicines.
Researchers identify mechanism by which dermatomyositis may develop in humans

Researchers identify mechanism by which dermatomyositis may develop in humans

UCI receives $4.2 million grant to study sporadic inclusion body myositis affecting aging adults

UCI receives $4.2 million grant to study sporadic inclusion body myositis affecting aging adults

Anti-phospholipid antibodies in severely ill patients not distinctive to COVID-19, says study

Anti-phospholipid antibodies in severely ill patients not distinctive to COVID-19, says study

Radiological images reveal how COVID virus can trigger the body to attack itself

Radiological images reveal how COVID virus can trigger the body to attack itself

SARS-CoV-2 triggers development of new-onset IgG autoantibodies in hospitalized COVID-19 patients

SARS-CoV-2 triggers development of new-onset IgG autoantibodies in hospitalized COVID-19 patients

EULAR publishes recommendations for management of rheumatic immune-related adverse events

EULAR publishes recommendations for management of rheumatic immune-related adverse events

Autoimmunity appears to be increasing in the U.S.

Autoimmunity appears to be increasing in the U.S.

Immune checkpoint inhibitors induce rheumatic and musculoskeletal diseases

Immune checkpoint inhibitors induce rheumatic and musculoskeletal diseases

Study reveals potential pathway for endothelial cells to avoid apoptosis

Study reveals potential pathway for endothelial cells to avoid apoptosis

Combination of Opdivo and Yervoy shows four-year survival benefits in patients with advanced melanoma

Combination of Opdivo and Yervoy shows four-year survival benefits in patients with advanced melanoma

Merck presents MK-1454 Phase 1 data for treatment of advanced solid tumors or lymphomas

Merck presents MK-1454 Phase 1 data for treatment of advanced solid tumors or lymphomas

Merck presents KEYNOTE-057 trial results for patients with high-risk non-muscle invasive bladder cancer

Merck presents KEYNOTE-057 trial results for patients with high-risk non-muscle invasive bladder cancer

Patients and families gather to gain more awareness, knowledge about myositis

Patients and families gather to gain more awareness, knowledge about myositis

Scleroderma Foundation names Tulane professor as 'Doctor of the Year'

Scleroderma Foundation names Tulane professor as 'Doctor of the Year'

CNDA approves KEYTRUDA for treatment of advanced melanoma

CNDA approves KEYTRUDA for treatment of advanced melanoma

Phase 3 study of KEYTRUDA monotherapy meets primary endpoint

Phase 3 study of KEYTRUDA monotherapy meets primary endpoint

A systematic approach towards diagnosis and treatment of rheumatoid arthritis

A systematic approach towards diagnosis and treatment of rheumatoid arthritis

Merck announces FDA acceptance of supplemental Biologics License Application for KEYTRUDA

Merck announces FDA acceptance of supplemental Biologics License Application for KEYTRUDA

Opdivo plus low-dose Yervoy shows promising results in treating renal cell carcinoma patients

Opdivo plus low-dose Yervoy shows promising results in treating renal cell carcinoma patients

New classification criteria offers faster, more accurate path to diagnosing myositis diseases

New classification criteria offers faster, more accurate path to diagnosing myositis diseases